A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
NCT ID: NCT07030868
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
1 participants
INTERVENTIONAL
2025-06-19
2025-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participation in the study will last about 11 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508
A Study of LY3549492 in Healthy Weight Adult Participants
NCT07085468
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
NCT07232732
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3549492 Dose 1
Participants will receive LY3549492 orally
LY6249492
Administered orally
LY3549492 Dose 2 Fast Titration
Participants will receive LY3549492 orally
LY6249492
Administered orally
LY3549492 Dose 2 Slow Titration
Participants will receive LY3549492 orally
LY6249492
Administered orally
Placebo
Participants will receive placebo orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY6249492
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Assigned male at birth
* Assigned female at birth, who are of non-childbearing potential
* Have type 2 diabetes
W8M-MC-CWMM:
* Have a BMI ≥27 kilograms per square meter (kg/m²)
* Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss
Exclusion Criteria
* Individuals who are of childbearing potential
* Have a history of acute or chronic pancreatitis
* Have any of the following cardiovascular conditions within 6 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure.
W8M-MC-CWMM:
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
* Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma
* Have poorly controlled hypertension
* Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease
* Have a history of symptomatic gallbladder disease within the past 2 years
* Have a lifetime history of suicide attempts
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HOPE Research Institute
Phoenix, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
NorCal Medical Research, Inc
Greenbrae, California, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Northeast Research Institute (NERI)
Fleming Island, Florida, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Charter Research - Winter Park
Orlando, Florida, United States
Charter Research - Lady Lake
The Villages, Florida, United States
Medical Research Partners
Ammon, Idaho, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
Knownwell
Needham, Massachusetts, United States
Lucida Clinical Trials
New Bedford, Massachusetts, United States
Headlands Research - Detroit
Southfield, Michigan, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
Clinvest Headlands Llc
Springfield, Missouri, United States
Las Vegas Medical Research
Las Vegas, Nevada, United States
Velocity Clinical Research, Syracuse
East Syracuse, New York, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
Monroe Biomedical Research
Monroe, North Carolina, United States
Lucas Research, Inc
Morehead City, North Carolina, United States
Lucas Research, Inc.
New Bern, North Carolina, United States
Quality Medical Research
Nashville, Tennessee, United States
IMA Clinical Research Austin
Austin, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
FutureSearch Trials of Dallas
Dallas, Texas, United States
PlanIt Research, PLLC
Houston, Texas, United States
Tekton Research - Fredericksburg Road
San Antonio, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States
Spectrum Medical, Inc.
Danville, Virginia, United States
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, United States
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., Argentina
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, Buenos Aires F.D., Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, , Argentina
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W8M-MC-GN02
Identifier Type: OTHER
Identifier Source: secondary_id
W8M-MC-CWMM
Identifier Type: OTHER
Identifier Source: secondary_id
27321
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.